摘要目的: 探讨甲壳质酶蛋白40(YKL-40)水平以及CXC趋化因子配体9(CXCL9)水平预测慢性阻塞性肺疾病(COPD)急性加重风险的意义。方法: 2019年10月至2021年10月,选择本院呼吸与危重症医学科150例COPD患者(女性38例,男性112例)和150例正常人作为研究对象。ELISA法测定血清YKL-40、CXCL9水平,计算住院时间。本次住院治疗后1年内追踪COPD急性加重次数。结果: 与对照组相比,在COPD病例中血清YKL-40水平显著升高(22.23±15.35ng/mL vs 63.96±13.66ng/mL,t=24.79,P<0.0001),而CXCL9水平无显著变化(17.92±9.01ng/mL vs 19.29±9.84ng/mL,t=1.26,P=0.210)。血清YKL-40随着COPD病例的GOLD分级升高而升高(1-2级:51.82±12.82ng/mL;3级:63.26±4.59ng/mL;4级:76.86±7.59ng/mL,F=96.92,P<0.0001)。与mMRC评分≤2的COPD患者相比,mMRC评分为2~3或≥3的COPD患者的血清YKL-40水平上调(58.35±15.37ng/mL vs 64.55±10.60ng/mL、68.79±12.66ng/mL,P<0.05)。在COPD患者中,血清YKL-40与FEV1(r=-0.668,P<0.001)和FEV1/FVC(r=-0.167,P=0.041)之间存在显著的负相关,以及血清YKL-40与IL-6(r=0.257,P=0.002)、TNF-α(r=0.522,P<0.001)和CRP(r=0.231,P=0.006)呈正相关。与住院时间≤8d的COPD患者相比,住院时间8~13d和≥13d的COPD患者血清YKL-40水平上调(57.31±15.82ng/mL vs 64.96±9.98ng/mL、69.79±11.58ng/mL,P<0.05)。急性加重次数≤2次患者入院时血清YKL-40水平显著低于急性加重次数>2次患者(58.77±15.66ng/mL vs 69.58±9.08ng/mL,t=5.17,P<0.001)。多元线性回归显示血清YKL-40与FEV1%呈负相关(OR=0.700,95%CI=-0.958,-0.272),和与住院时间≥13d呈正相关(OR=1.125,95%CI=1.007,1.472)。结论: 入院时血清YKL-40水平与COPD患者的严重程度和不良预后呈正相关。
Abstract：Objective: To explore the significance of chitin enzyme protein 40(YKL-40) and CXC chemokine ligand 9(CXCL9) in predicting the acute exacerbation risk of chronic obstructive pulmonary disease (COPD). Methods: From October 2019 to October 2021, 150 COPD patients (38 females and 112 males) and 150 normal people were selected as the research objects. Serum YKL-40 and CXCL9 levels were measured by ELISA, and the hospitalization time was calculated. Follow up the number of acute exacerbations of COPD within one year after this hospitalization. Results: Compared with the control group, the serum YKL-40 level in COPD patients increased significantly (22.23±15.35 ng/ml vs 63.96±13.66 ng/ml, t=24.79, P<0.0001), while the level of CXCL9 did not change significantly (17.92±9.01 ng/ml vs 19.29±9.84 ng/mL,t=1.26, P=0.210). Serum YKL-40 increased with the increase of GOLD grade in COPD patients (grade 1-2: 51.82 ±12.82 ng/ml; Grade 3: 63.26±4.59 ng/ml; Grade 4: 76.86±7.59 ng/mL, F=96.92, P<0.0001). Compared with COPD patients with mMRC score ≤ 2, the serum YKL-40 level of COPD patients with mMRC score of 2~3 or ≥3 was increased (58.35±15.37 ng/ml vs 64.55±10.60 ng/ml, 68.79±12.66 ng/mL, P<0.05). In COPD patients, serum YKL-40 was negative correlated with FEV1(r=-0.668, P<0.001) and FEV1/FVC(r=-0.167, P=0.041), and serum YKL-40 was positively correlated with IL-6(r=0.257, P=0.002), TNF-α(r=0.522, P<0.001) and CRP(r=0.231, P=0.006). Compared with COPD patients whose hospitalization time was ≤8 d, the serum YKL-40 level of COPD patients whose hospitalization time was 8~13 d and ≥13 d was increased (57.31±15.82 ng/ml vs 64.96±9.98 ng/ml, 69.79±11.58 ng/mL, P<0.05). The level of serum YKL-40 in patients with acute exacerbation ≤2 times was significantly lower than that in patients with acute exacerbation > 2 times (58.77±15.66 ng/ml vs 69.58±9.08 ng/ml, t=5.17, P<0.001). Multiple linear regression showed that serum YKL-40 was negatively correlated with FEV1% (OR=0.700, 95%CI=-0.958, -0.272) and positively correlated with hospitalization time ≥ 13 d (OR=1.125, 95%CI=1.007, 1.472). Conclusion: The level of serum YKL-40 at admission is positively correlated with the severity and poor prognosis of COPD patients.
何芸, 刘霖, 韩瑞萍, 戴伟, 吴艳霞. YKL-40水平预测慢性阻塞性肺疾病急性加重风险的意义研究[J]. 河北医学, 2023, 29(12): 2054-2059.
HE Yun, LIU Lin, HAN Ruiping, et al. Significance of YKL-40 Levels in Predicting the Risk of Acute Exacerbation in Chronic Obstructive Pulmonary Disease. HeBei Med, 2023, 29(12): 2054-2059.
[1] 张炜,丁朵,王蕾.慢性阻塞性肺疾病相关肺动脉高压中肺动脉压力与肺功能的关联性研究[J].西安交通大学学报:医学版,2022,43(6):889-894. [2] 陈训春,李名兰,潘碧云,等.TLR4/NF-κB信号通路激活LncRNA RP11-20G6调控慢性阻塞性肺疾病气道炎症和重塑[J].安徽医科大学学报,2022,57(4):586-593. [3] Singh D,Bafadhel M,Brightling C E,et al.Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease[J].Am Respir Crit Care Med,2020,202(5):660-671. [4] Jeong M H,Han H,Lagares D,et al.Recent advances in molecular diagnosis of pulmonary fibrosis for precision medicine[J].ACS Pharmacol Transl Sci,2022,5(8):520-538. [5] Coriati A,Bouvet G F,Masse C,et al.Ykl-40 as a clinical biomarker in adult patients with cf:Implications of a chi3l1 single nucleotide polymorphism in disease severity[J].Cyst Fibros,2021,20(6):e93-e99. [6] Jiang Y L,Fei J,Cao P,et al.Serum cadmium positively correlates with inflammatory cytokines in patients with chronic obstructive pulmonary disease[J].Environ Toxicol,2022,37(1):151-160. [7] Kamle S,Ma B,He C H,et al.Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19[J].JCI insight,2021,6(21):148749. [8] Bouvet G F,Bulka O,Coriati A,et al.Peripheral blood mononuclear cell response to YKL-40 and Galectin-3 in cystic fibrosis[J].Cytokine,2021,146:155635. [9] Hakansson K E J,Ulrik C S,Godtfredsen N S,et al.High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD[J].Int Chron Obstruct Pulmon Dis,2020,15:733-743. [10] Hasegawa T,Okazawa T,Uga H,et al.Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma[J].Allergy,2019,74(12):2515-2518.
2023, Vol. 29 
冀公网安备13080202000677号